Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share (Tables)

v3.21.1
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2020
Net Loss Per Share  
Schedule of reconciliation of net loss

 

 

 

 

 

 

 

 

 

For the Years Ended

 

 

December 31,

 

    

2020

    

2019

Net loss

 

$

(26,381,389)

 

$

(20,384,716)

Net loss - Non-controlling interest

 

 

(331,652)

 

 

(367,148)

Net loss attributable to Heat Biologics, Inc.

 

$

(26,049,737)

 

$

(20,017,568)

 

 

 

 

 

 

 

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted

 

 

15,982,568

 

 

4,754,542

Net loss per share attributable to Heat Biologics, Inc. —basic and diluted

 

$

(1.63)

 

$

(4.21)

 

Schedule of potentially dilutive securities

 

 

 

 

 

 

    

2020

    

2019

Outstanding stock options

 

1,480,139

 

437,603

Restricted stock subject to forfeiture and restricted stock units

 

241,828

 

183,796

Outstanding common stock warrants

 

758,939

 

1,290,103